← Eichor
Condition: Blastic Plasmacytoid Dendritic Cell Neoplasm Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Blastic Plasmacytoid Dendritic Cell Neoplasm

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Phase 1 · 31 location(s) · Therapeutic Advances in Childhood Leukemia Consortium · NCT05476770Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 · 2 location(s) · Mayo Clinic · NCT06712810Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523555CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial
EARLY_Phase 1 · 1 location(s) · Institute of Hematology and Blood Transfusion, Czech Republi · NCT06765876Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers
Phase 2 · 10 location(s) · Fred Hutchinson Cancer Center · NCT03779854HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Ste
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03326921CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
Phase 1 · 2 location(s) · St. Jude Children's Research Hospital · NCT04318678Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06690827Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
Phase N/A · 22 location(s) · Immune Oncology Research Institute · NCT05430971SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplas
Phase 1 · 3 location(s) · Dana-Farber Cancer Institute · NCT03113643Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dend
Phase 1/Phase 2 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06006403Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Bl
Phase 2 · 34 location(s) · French Innovative Leukemia Organisation · NCT07007052Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hem
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06013423Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04216524
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.